Analysis

Enanta Pharmaceuticals, Inc. (ENTA) Stock Analysis

Enanta Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ENTA.

websiteENTA/analysis/ENTA

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ENTA.

Stock profile

Ticker

ENTA

Asset type

Stock

Market cap

$368.1M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Enanta Pharmaceuticals, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ENTA primary listing
  • 9EP
  • A1T7BJ

Latest Enanta Pharmaceuticals, Inc. news

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute...

WATERTOWN, Mass., June 23, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infectio...

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial V...

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

WATERTOWN, Mass., May 11, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infection...

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society ...

WATERTOWN, Mass., May 04, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infection...

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Deve...

Phase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026

Research sections

Valuation

Review valuation context for Enanta Pharmaceuticals, Inc..

Future growth

Review future growth context for Enanta Pharmaceuticals, Inc..

Past performance

Review past performance context for Enanta Pharmaceuticals, Inc..

Financial health

Review financial health context for Enanta Pharmaceuticals, Inc..

Dividend

Review dividend context for Enanta Pharmaceuticals, Inc..

Management

Review management context for Enanta Pharmaceuticals, Inc..

Ownership

Review ownership context for Enanta Pharmaceuticals, Inc..

Other information

Review other information context for Enanta Pharmaceuticals, Inc..

Community

Review community context for Enanta Pharmaceuticals, Inc..